AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT07931573
- Phase
- Phase 3
- Recruitment
- Not yet enrolling
- Sponsor
- Novo Nordisk A/S
- Design
- Randomized
- Comparator
- Zenagamtide; Semaglutide; Placebo
- Planned enrollment
- 1200
- Endpoint
- Change in glycated haemoglobin (HbA1c) [non-inferiority]
Study ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Slovakia, Spain, United Kingdom, United States.
Primary data collection: Jul 4, 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1